DVAX
Dynavax Technologies·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DVAX
Dynavax Technologies Corporation
A biotech company that develops and commercializes vaccines and immune-oncology therapies
2100 Powell Street, Suite 720, Emeryville, CA 94608
--
Dynavax Technologies Corporation was incorporated on August 29, 1996 under the name of California Double Helix Structure Corporation and changed its name to Dynavax Technologies Corporation in September 1999. The company was restructured in Delaware in 2000. The Company is a fully integrated biopharmaceutical company focused on harnessing the power of the body's innate and adaptive immune responses through Toll-like receptor (" TLR ") stimulation. Their first commercial product, HEPLISAV-B (hepatitis B vaccine (reconstituted), adjuvant), was approved by the U.S. Food and Drug Administration (" FDA ") in November 2017 for the prevention of infection caused by all known hepatitis B subtypes of the virus in adults over the age of 18 years. They started shipping HEPLISAV-B commercially in January 2018. Their development work has focused on stimulating the innate immune response to treat cancer in combination with other immunomodulators. Their main research immuno-oncology product is SD-101, which is currently undergoing Phase 2 clinical study evaluation, and DV281 is undergoing Phase 1 safety study.
Earnings Call
Q1/2025
Estimate EPS0.02
Actual EPS-0.77
Estimate Revenue68.39M
Actual Revenue68.16M
Dynavax's Q1 2025 Earnings Call: Key Contradictions on Shingles Study, Medicare Access, and Market Share Expectations
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.14
Actual EPS0.14
Estimate Revenue86.66M
Actual Revenue95.44M
Dynavax's Q2 2025: Unraveling Key Contradictions in Strategy, Data, and Market Shifts
Aug 07,2025 11:03
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.12
Actual EPS0.21
Estimate Revenue94.00M
Actual Revenue94.90M
Dynavax's Q3 2025: Contradictions Emerge on Market Share Aspirations, Retail Vaccination Shift Impact, Oral Vaccine Trial Design, and Shingles Vaccine Differentiation
Nov 05,2025 07:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
DVAX has released its 2025 Q3 earnings. EPS was reported at 0.21, versus the expected 0.12, beating expectations. The chart below visualizes how DVAX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DVAX has released its 2025 Q3 earnings report, with revenue of 94.88M, reflecting a YoY change of 17.67%, and net profit of 26.93M, showing a YoY change of 53.05%. The Sankey diagram below clearly presents DVAX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
